Mylan (MYL) Pulled from Morgan Stanley Conference Due to Scheduling Conflict - Spokesperson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Mylan (MYL) agrees to brief House Committee next week - Bloomberg
September 2, 2016 12:37 PM EDTMylan (NASDAQ: MYL) agrees to brief House Committee next week, according to Bloomberg.
... MoreMylan (MYL) Denies Rumors CEO Bresch to Step Down
September 2, 2016 10:43 AM EDTEmbattled EpiPen maker Mylan (NASDAQ: MYL), in an email to StreetInsider, denied rumors that its CEO Heather Bresch will step down. Comments were in response to earlier speculation following a DealReporter story.
A Mylan spokesperson also told StreetInsider that it pulled out... More
Rumors Abound on Mylan (MYL) After Conference Cancellation
September 2, 2016 9:48 AM EDTThere are a lot of rumors floating around Mylan (NASDAQ: MYL) after the company was said to pull form a Morgan Stanley conference. One rumors is the CEO is going to leave.
Shares are down 2.2% early following Hillary Clinton outline on curbing drug price hikes.
... More
